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Abstract
Background: The Assessment of Quality of Life (AQoL) utility instrument was psychometrically
developed for the general population. This study aimed to explore its potential as an osteoarthritis
(OA) outcome measure.
Methods:  W O M A C ,  L e q u e s n e  i n d e x ,  S F - 3 6 ,  V i s u a l  a n a l o g u e  s c a l e s  a n d  t h e  A Q o L  w e r e
administered to 222 people with OA. The ability of each questionnaire to detect differences
between groups was based on (i) self-rated health (SRH) and, (ii) differences between people on an
orthopedic waiting list (WL) vs people with OA in the community (C). Comparisons included effect
size, relative efficiency and receiver operator characteristic curves.
Results:  All instruments detected differences between groups; however no one instrument
exhibited superior efficiency. The AQoL demonstrated strong psychometric properties.
Conclusion: The AQoL has equivalent performance to comparator questionnaires commonly
used in OA research and would be a useful adjunct to well-established disease specific scales. The
AQoL has important advantages; brevity (12 items), facilitates comparisons between disease
groups, and delivers a utility score that can be used in health economic evaluations.
Background
Osteoarthritis (OA) represents a significant public health
problem and disease burden globally, resulting in major
disability and pain in affected individuals and significant
health care costs for associated disease management [1].
Given the high disability and poor quality of life associ-
ated with OA, patient-perceived outcomes are considered
important when evaluating interventions. Disease specific
outcome measures are favored as they capture specific
symptomatology, e.g., pain and stiffness, and functional
ability. This is particularly the case for clinical trials [2].
One commonly applied disease-specific scale is the West-
ern Ontario and McMaster Arthritis Index (WOMAC)
which provides scores with wide currency, providing
Published: 23 March 2006
Health and Quality of Life Outcomes 2006, 4:19 doi:10.1186/1477-7525-4-19
Received: 06 June 2005
Accepted: 23 March 2006
This article is available from: http://www.hqlo.com/content/4/1/19
© 2006 Whitfield et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Health and Quality of Life Outcomes 2006, 4:19 http://www.hqlo.com/content/4/1/19
Page 2 of 10
(page number not for citation purposes)
researchers with readily interpretable information on OA
outcomes [3,4].
In the face of the demands on limited health budgets there
is an increasing imperative for cost effectiveness analyses
of new technologies. This means outcome measures are
required that can establish both the effectiveness of new
technologies or new approaches to care and are also suit-
able as the denominator in cost-effectiveness analyses.
This interest extends to comparisons of performance
(including impacts on quality of life and mortality) of
interventions using cost effectiveness or cost utility analy-
ses across disease categories and disease stages. Disease
specific health status outcome measures are unsuitable for
these types of analyses. Generic health related quality of
life (HRQoL) measures can, in some circumstances, assist
with inter-disease group comparisons [5] but cost-utility
analyses require generic utility HRQoL instruments [1].
The Assessment of Quality of Life (AQoL) instrument is a
generic utility HRQoL tool, developed using stringent psy-
chometric methods and is sensitive to a wide range of
health states [6] and has been validated for use in a range
of patient groups [7-9]. The AQoL has been demonstrated
to have excellent responsiveness in prior studies. In the
frail elderly and in people who have had a stroke the
AQoL has been shown to be more responsive than the SF-
36 and more responsive than stroke-specific instruments
[10,11]. This is remarkable given that the AQoL is a short
multi-attribute utility instrument.
In this study we assessed the measurement properties of
the AQoL in a large sample of people with OA, a common
chronic condition, and compared its performance with
other commonly used disease specific and a generic
HRQoL instruments.
Methods
The data used in this study were collected as part of a sur-
vey of health status of people with OA to assist in priority
setting for the disease, conducted in Melbourne, Australia
[12]. The sampling frame was designed to reflect the pos-
sible range of disease severity of participants in published
trials, from severe to mild disease. Participants with clini-
cally diagnosed OA were recruited from a hospital-based
orthopedic surgery waiting list, public hospital and pri-
vate rheumatology (ambulatory care) clinics. A commu-
nity-based sample of people with self-reported OA were
also recruited through membership of the Victorian
Arthritis Foundation. Recruitment relied on open, anony-
mous, voluntary participation with no follow-up. In total
331 individuals completed and returned surveys (53% of
those approached). However, only 222 of these partici-
pants completed the six questionnaires of interest
(WOMAC, AQoL, SF-36 and the three visual analogue
scales) where scores were calculable. Given our objective
of validating the AQoL against the other instruments we
restricted our analyses to those participants with complete
response sets (n = 222). The Lequesne index for hip OA
was only completed by participants with hip OA (n =
115). Participants (20%) on the orthopedic waiting list
represent the high severity extreme, with their disease clin-
ically judged to require joint replacement surgery. By con-
trast, the community-based sample (50%) was regarded
as having less severe disease. Institutional Ethics Commit-
tee approval was given by the Human Research Ethics
Committee at the Royal Melbourne Hospital.
Measures
The AQoL instrument is a generic 12-item utility HRQoL
tool incorporating four dimensions: independent living,
social relationships, physical senses and psychological
well-being [5]. These subscales are weighted between 0.0
(death) and 1.0 (full health). Scores for the four dimen-
sions are combined into an overall utility score extending
from minus 0.04 (worst possible HRQoL state) through
0.00 (equivalent to death) to 1.00 (full HRQoL). The time
trade-off method was used to determine utility weights in
a general population sample. The instrument has been
well validated in a range of settings for delivery via self-
administration, face-to-face or by proxy and takes approx-
imately 5 minutes to complete [8,10,11].
The WOMAC (Western Ontario McMaster Universities
Osteoarthritis Index) is a self-rating instrument designed
for patients with lower extremity disease. WOMAC con-
sists of three subscales: pain, stiffness and physical func-
tioning [4]. Subscale scores sum multi-item responses,
and a global WOMAC score summates the subscales. Glo-
bal scores range from 0 (no disease) to 96 (worst disease)
and are standardized (0 – 100). The instrument consists of
24 items and takes 5 to 7 minutes to complete. Validation
studies have supported the validity, reliability and respon-
siveness of the WOMAC [3,4,13].
There are two Lequesne's severity indices which were
developed for use in patients with (1) hip and (2) knee
OA [14]. Each index generates a comparable single sum-
mated score which comprises three dimensions: pain/dis-
comfort, maximum distance able to walk and activities of
daily living. Scores extend from 00 (no disease) to 24
(worst disease). Categorized scores indicate level of hand-
icap: 1–4 minor, 5–7 moderate, 8–10 severe, 11–13 very
severe and > 14 extremely severe. Scores above 10 to 12
indicate surgical treatment is required [14]. Although
designed as a clinical assessment tool it has been consid-
ered appropriate for self-administration and has been val-
idated and applied in clinical trials [14].
The SF-36 is a widely used generic health status instru-
ment [5,15,16]. It comprises eight multi-item subscalesHealth and Quality of Life Outcomes 2006, 4:19 http://www.hqlo.com/content/4/1/19
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each containing between two and ten items: physical
functioning, role physical, bodily pain, general health,
vitality, social functioning, role emotional and mental
health. Subscales are scored separately, weighted,
summed and transformed onto a 0 (poor health) to 100
(excellent health) scale. Two summary composite scores
can be constructed: mental component score (MCS) and
physical component score (PCS). The SF-36 is designed
for self-administration and takes approximately six to
nine minutes to complete [16,17].
Three classical visual analogue scales (VAS) covering pain
and movement restriction were included. Respondents
indicated their experience of pain and restriction over the
past week by placing a mark along a horizontal 10 cm line
anchored by 0 (no pain) and 100 (worst possible pain).
VAS are favored for their simplicity and high correlation
with verbal rating scales [18].
Statistical analyses
Spearman's rank correlation coefficients were used to
assess construct validity between the AQoL and WOMAC,
SF-36 and VASs. AQoL dimensions intended to measure a
similar phenomenon to other scales, were expected to cor-
relate highly. Similarly, AQoL dimensions were expected
to have weak correlations with divergent dimensions on
other scales. For example, the AQoL's independent living
subscale was expected to correlate highly with the
WOMAC and SF-36 physical function scores and to
exhibit weak correlation with the SF-36 social function.
Given the Lequesne and AQoL scales both measure hand-
icap we expected a high correlation between their sum-
mary scores [6,14]. Given that the AQoL measures overall
Health-related Quality of Life, we expected that the utility
score would be moderately correlated with individual ele-
ments of OA-related HR-QOL in each of the comparator
scales; i.e., health status (SF-36) and arthritis symptoms of
pain and limitations (WOMAC, VAS). The classification
of the magnitude of correlation coefficients was based on
Cohen's rule where < 0.3 is considered a low correlation,
0.3 to 0.6 moderate and > 0.6 high [19].
We assessed the ability of each questionnaire to detect dif-
ferences between groups through a series of known group
validations [20,21]. One set of comparisons was based on
self-rated health measured by a five-point scale converted
to a dichotomous variable, poor/fair health vs. good/very
good/excellent health. The second comparison was
between people on the orthopedic waiting list (OWL)
with OA and individuals in the community-based group.
Known group validation included comparison of AQoL
mean scores against the other scales using Student's t tests.
We also calculated effect size (ES), relative efficiency (RE)
and receiver operator characteristics (ROC) curves to
quantify the magnitude of the discriminative performance
of the instruments.
Effect size (ES) is the standardized mean difference
between groups. We used the pooled standard deviation
as the measure of variance. Effect size values of less than
0.2 can be considered small, values of 0.5 as moderate and
scores of 0.8 and greater as large [20,22]. Relative effi-
ciency (RE) is the ratio of the squares of the t statistic,
where in each case the comparison is against the AQoL
score. The RE is commonly used to compare the relative
abilities of instruments to detect differences between
groups known to be different [20]. Receiver operator char-
acteristics (ROC) curves synthesize information about the
sensitivity (proportion of true differences detected by the
instrument) and specificity (proportion of individuals
truly not different and detected as such) of an instrument
against an external 'known difference' criterion, such as
categorical differences in severity of disease [20,23]. The
power of discrimination can be represented by the area
under the ROC curve (AUC), which plots sensitivity
against 1 minus specificity. An AUC of 1.0 (100%) repre-
sents perfect discriminatory performance and an AUC of
0.5 (50%) implies that an instrument can discriminate
between groups no better than would be expected by
chance. Using the standard errors for the estimated AUCs
we also performed tests to compare the relative perform-
ance of the AQoL utility scale against the other instru-
ments. Z statistics were calculated with the critical value
set at Z > 1.96, p < 0.05. Given that all instruments were
applied to the same data, we adjusted standard errors to
account for intra-group correlation before calculating Z
statistics [24]. Relative performance was also estimated by
the absolute performance gain (APG) of the AQoL against
the other instruments [25]. APG analysis compares instru-
ment's AUCs against a nominated reference AUC to eval-
uate the relative information gain of one instrument over
another [25]. In this study we nominated the AQoL as the
reference AUC.
This series of tests was repeated in parallel for a subset of
the respondents, who had completed the Lequesne index
(hip OA only). For this subset, the comparisons were lim-
ited to the AQoL, Lequesne's index, and WOMAC sum-
mary score.
Liang et al suggest that where a number of tests are con-
ducted to assess instrument performance then a simple
method of comparison is to rank order the relative per-
formance of the instruments within each test [23,26]. We
present this information for each of the known group
analyses. We also compare the AQoL with disease severity
by examining the relationship between AQoL and
Lequesne instrument scores grouped by previously
defined severity of handicap [14].Health and Quality of Life Outcomes 2006, 4:19 http://www.hqlo.com/content/4/1/19
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Demographic and clinical details of the study participants
are presented in Table 1. The majority of respondents
(50%) were from the community whilst 20% and 30%
came from the Orthopedic waiting list (OWL) and spe-
cialist rheumatology clinics respectively. Mean age was 66
(range 42–90) and 67% were female. Approximately three
quarters of respondents reported ≥ 2 joint sites affected by
OA. A total of 115 reported hip OA and had completed
the Lequesne questionnaire that categorized 68% of these
individuals as having either extreme or very severe handi-
cap. Of the total sample, 24% reported either 'poor' or
'fair' general health.
The mean (sd) AQoL score was 0.47 (0.22). These data
were not significantly skewed and scores did not cluster at
scale extremes suggesting floor or ceiling effects. Other
summary scales also had normal distributions. The mean
scores of the SF-36 PCS and MCS were 30.7 (9.0) and 47.6
(12.2) respectively. WOMAC mean composite score was
45.4 with standard deviation 18.3. The mean Lequesne
index score was 12.4 (4.1). The VAS mean scores for aver-
age pain, pain at rest and activities of daily living (ADL)
were 50.3 (23.6), 32.2 (23) and 43.3 (25.8) respectively.
Construct validity
Associations between the AQoL and the other instruments
are shown in Table 2. It was hypothesised that AQoL Inde-
pendent living scale would be highly correlated with like
scales; this was observed for the SF-36 Physical function
scale, WOMAC Physical function and summary score, VAS
Restriction in ADL (all R = 0.59) and also the Lequesne
scale (R = -0.71). The AQoL Psychological well-being was
highly correlated with SF-36 bodily pain (R = 0.60) and
WOMAC pain (R = -0.58) and summary score (R = -0.59).
The AQoL Physical senses scale is unlike any of the com-
parators and was consistently weakly associated with all
other scales (R < = 0.26).
It was hypothesised that the AQoL utility would exhibit a
moderate correlation with comparator scales which were
key elements of OA-related HR-QoL (pain and ADL limi-
tations). High to moderate correlations were observed for
the WOMAC scales (R < = -0.63), the VAS scales (R > -
0.56) and a very high correlation with the Lequesne index
(R = -0.76). Grouping of the Lequesne index into severity
categories and plotting this against AQoL utility illustrates
this relationship (Figure 1).
Discriminatory Validation
Orthopedic Waiting List (OWL) v Community group comparisons
Known-group comparisons of the OWL versus the com-
munity-based group are shown in Table 3. The AQoL per-
formed relatively well on the tests of discriminative
ability, as did the WOMAC and VASs. The SF-36 per-
formed least well across all tests. Rank ordering of the per-
formance is displayed in Table 4. Effect sizes were largest
for the WOMAC physical function (ES, -0.82), its sum-
mary score (ES, -0.79) and VAS pain score (ES, 0.74). The
AQoL showed moderate effect sizes for its summary score
(ES, 0.66) but the Psychological wellbeing scale exhibited
the largest effect size (ES, 0.88).
The Relative Efficiency (RE) statistic provided an addi-
tional comparison of the ability of each scale to detect dif-
ferences between groups. The RE of the AQoL utility was
referenced to 1.0 which revealed that this scale performed
better than all SF-36 scales (RE, 0.01–0.57), the WOMAC
pain (RE, 0.84) and stiffness (RE, 0.60) subscales and the
VAS ADL scale (RE, 0.64). WOMAC summary (RE, 1.46)
and VAS pain scale (RE, 1.26) outperformed the other
instruments on this measure.
For the ROC analyses, WOMAC physical function (AUC,
0.71), summary (AUC, 0.70) and VAS pain (0.70) showed
the best discrimination. The AQoL utility (AUC, 0.67)
also showed substantial discriminatory ability. Of the SF-
36 dimensions, Physical function (AUC, 0.67) performed
best. A number of subscales and summary scale scores per-
formed no better than chance with AUC values close to
AQoL summary utility score for individuals categorized  according to the Lequesne Index of severity (hip), n = 159 (9  missing values) Figure 1
AQoL summary utility score for individuals categorized 
according to the Lequesne Index of severity (hip), n = 159 (9 
missing values).
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0.0Table 1: Demographic and clinical details of the study sample




 (N = 66)
Orthopedic 
Waiting
 List (N = 45)
Community 
Group
 (N = 111)
No. % No. % No. % No. %
Age group (years) [missing values = 3] < 55 30 14 11 17 6 14 13 12
5 5  t o  5 9 2 9 1 391 43 71 7 1 5
60 to 64 33 15 11 17 5 11 17 15
6 5  t o  6 9 3 5 1 681 281 8 1 9 1 7
70 to 74 39 18 11 17 7 16 21 19
75 to 79 32 15 6 9 10 23 16 15
≥ 8 0 2 1 1 091 451 17 6
Gender F e m a l e 1 4 9 6 74 46 72 45 38 17 3
Male 73 33 22 33 21 47 30 27
BMI groupings* 
U n d e r w e i g h t <  1 8 . 5 00000000
Normal 18.5 to 24.9 64 31 22 37 10 24 32 30
Overweight 25.0 to 29.9 76 37 26 43 18 43 32 30
Obesity I 30 to 34.9 40 19 9 15 11 26 20 19
Obesity II 35.0 to 39.9 19 9 2 3 3 7 14 13
Extreme Obesity [missing values = 14] ≥ 4 0 94120088
Most common joints affected K n e e 1 5 5 7 04 46 72 86 28 37 5
Hip 118 53 25 38 16 36 68 61
B a c k 1 1 0 5 02 43 61 63 67 06 3
H a n d / w r i s t 1 0 9 4 92 53 81 63 66 86 1
Hip, knee, foot/
ankle
1 7 9 8 13 55 33 88 4 1 0 1 9 1
Lequesne scores grouped for severity of handicap (hip 
only) [n = 115, missing values = 14]
Extremely 
severe
53 46 11 46 17 61 25 40
V e r y  s e v e r e 2 5 2 272 951 8 1 3 2 1
Severe 21 18 2 8 6 21 13 21
M o d e r a t e 1 3 1 1 2800 1 1 1 7
M i l d 33280012
Self-rated general health Excellent health 15 7 8 12 2 4 5 5
Very good 
health
60 27 19 29 10 22 31 28
Good health 93 42 25 38 20 44 48 43
Fair health 40 18 10 15 10 22 20 18
P o o r  h e a l t h 1 4 6463776
* BMI classifications as per National Heart, Lung, and Blood Institute (USA) Guidelines
0.50. Figure 2 shows the ROC curves for the AQoL and WOMAC summary scores and the
two SF-36 composite measures. Z statistic calculations show that the AUC for the AQoL
utility (reference value) was not significantly different from the AUC of other instru-
ments. The sole exception was the AQoL dimension physical senses with Z statistic, 1.96
(Z > 1.96, p < 0.05) performing less well.
Absolute performance gain analyses showed that AQoL utility (reference value) tended
to have a positive information gain against other instruments and subscales. Exceptions
ranged from SF-36 physical function (0.5%) to WOMAC physical function (8%) which
tended to outperform the AQoL utility. Analyses comparing Lequesne's index with the
other instruments in the hip disease sub-sample indicated comparable performance withHealth and Quality of Life Outcomes 2006, 4:19 http://www.hqlo.com/content/4/1/19
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any differences in efficiency not statistically significant
(results not shown).
Self-rated General Health group comparisons
Known-groups comparisons for good health versus poor
health are shown in Table 5. The general health and MCS
dimensions of the SF-36 were excluded from these analy-
ses, as self-rated general health is a function of the scales.
The AQoL performed relatively well on the tests of dis-
criminative ability, as did the WOMAC and VAS. Rank
ordering of the instruments is displayed in Table 4. Effect
sizes are largest for the AQoL utility (ES, -1.00), WOMAC
summary (ES, 0.92) and the SF-36 subscales bodily pain
(ES, -1.10) and vitality (ES, -1.12). All other instrument
subscale and summary scores show moderate to large
effect sizes (ES, 0.53–0.98) with the exception of the
AQoL physical senses dimension (ES, -0.23). AQoL utility
(RE referenced to 1.0) performed better than WOMAC
(RE, 0.65–0.84), VAS (RE, 0.36–0.49) and SF-36 scales
(RE, 0.44–0.89) other than SF-36 bodily pain (RE, 1.21)
and vitality (RE, 1.26).
All instruments and dimensions performed similarly in
the ROC analyses with AUC ranging from 0.66 to 0.80.
The AQoL physical senses (AUC 0.56, p = 0.19) per-
formed no better than chance. The ROC curves for the
AQoL and WOMAC summary and the SF-36 composite
measures are shown in Figure 3. Z statistic calculations
show that the AUC for the AQoL utility (reference value)
was not significantly different from the AUC of other
instruments or dimensions. The only exception was the
weakly discriminating AQoL physical senses scale (Z sta-
tistic 2.06; Z > 1.96, p < 0.05). Absolute performance gain
analyses show the AQoL utility (reference value) had a
positive information gain against most other instruments.
Analyses comparing Lequesne's index with the other
instruments in the hip disease sub-sample indicated com-
parable performance with any differences in discrimina-
tion and efficiency not statistically significant (results not
shown).
Discussion
This study has provided strong evidence that the AQoL
has strong construct validity and strong discriminative
validity for use in people with OA. This finding, in con-
junction with prior studies indicating the AQoL's respon-
siveness, suggests the AQoL is a promising tool for OA
clinical and epidemiological research. Further, the AQoL
is a parsimonious 12-item instrument returning informa-
tion on four domains and providing a single utility score.
When compared with commonly used disease specific
(WOMAC & Lequesne) and generic (SF-36) measures the
AQoL performs as well or better with high discriminatory
Receiver Operator Characteristic (ROC) curves for per- formance of the AQoL, WOMAC, SF36 physical component  summary (PCS) score and VAS in discriminating between  individuals with self rated poor vs good health Figure 3
Receiver Operator Characteristic (ROC) curves for per-
formance of the AQoL, WOMAC, SF36 physical component 
summary (PCS) score and VAS in discriminating between 
individuals with self rated poor vs good health.
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Receiver Operator Characteristic (ROC) curves for per- formance of the AQoL, WOMAC, SF-36 physical component  summary (PCS) score and VAS in discriminating between  individuals on the waiting list vs Community. Figure 2
Receiver Operator Characteristic (ROC) curves for per-
formance of the AQoL, WOMAC, SF-36 physical component 
summary (PCS) score and VAS in discriminating between 
individuals on the waiting list vs Community.
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validity. The AQoL was also found to have strong conver-
gent and divergent validity supporting its overall construct
validity [18]. Furthermore, assuming that the Lequesne
algorithm represents severity of handicap due to OA, the
high correlation between it and the AQoL utility supports
criterion validity of the AQoL in this disease group [2].
The principal aspects of handicap for people with OA
results through pain, limitations and the impact that these
have on peoples' overall life, including how primary OA
symptoms pervade social and psychological well-being
[27]. The AQoL is designed to capture these through pref-
erences in a weighted multi-attribute utility measure
expressed on a life-death scale. In this way, the AQoL pro-
vides a single score that represents the disutility ('undesir-
ableness') of their overall health status.
As there is no consensus on a definitive discriminative
test, we applied a range of measures to examine perform-
ance of each questionnaire [28]. Rank ordering the instru-
ments within these tests shows the AQoL performs well
[26]. Consistent with other studies we also explored ROC
and APG analyses to empirically test instruments' relative
efficiency and performance [, , , ]. Although the results
comparing the known groups based on clinical difference
(OWL vs community group) appear to suggest the disease
specific outcomes perform better, our empirical analyses
show that the difference is not statistically significant.
There has been some debate about the relative merits of
using generic versus disease specific measures across set-
tings and disease groups [2,18,23,28]. Disease specific
outcome measures are often favored in clinical trials
where there is a need for a sensitive measure of small but
important clinical changes and a need to rapidly catego-
rize patients [18]. This is because generic instruments are
viewed as relatively insensitive to these small 'clinically
important' changes and cover irrelevant domains. Other
cited advantages of disease specific outcome measures
include suitability for self-administration, brevity, sim-
plicity of administration and calculation of summary
scores and low cost [18]. However, it is recognized that
generic measures facilitate comparison between studies,
as they are broadly applicable across a range of severity
and type of diseases, populations and different interven-
tions [18]. It is also postulated that the breadth of dimen-
sions explored using generic HRQoL questionnaires can
capture the full effects, including unanticipated impacts,
of an intervention [2]. A way of resolving the issue of
whether generic or disease specific questionnaires should
be administered is through combined use of generic and
disease specific outcome measures in clinical trials
[2,18,28]. Others reject this proposal arguing overlapping
content and excessive questionnaire items impose an
unacceptable burden on respondents reducing compli-
ance [20]. This suggests that investigators should use the
most valid and parsimonious instruments available that
are able to detect the hypothesized outcomes. Also where
investigators require evidence of the overall and compar-
ative value of an intervention, use of a generic utility
instrument is recommended [20]. Given that utility
instruments reflect both patients' health status and valua-
tion of health state [2] their scores can be incorporated
into cost utility studies facilitating comparative economic
appraisals of interventions.
Conclusion
The AQoL utility instrument exhibits comparable effi-
ciency and performance relative to more commonly used
health outcome measures in OA studies, i.e., WOMAC
and SF-36. In addition the AQoL has only 12 items com-
pared with the 24 or 36 items of the WOMAC and SF-36
respectively. As a generic index the AQoL facilitates com-
parisons across groups and also provides a utility score
suitable for economic analyses. For these reasons, and
prior strong evidence of its validity in other settings
including responsiveness [7-9] the AQoL appears to be a
suitable adjunct to disease specific questionnaires in clin-
ical trials and epidemiological studies of people with OA.
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Table 2: Spearman's correlation coefficients between scales










AQOL Utility 0.78 0.75 0.38 0.77
SF-36
Physical Function 0.59 0.34 0.17 0.43 0.59
Role Physical 0.38 0.32 0.05 0.31 0.39
Bodily Pain 0.54 0.43 0.07 0.60 0.63
General Health 0.31 0.31 0.14 0.48 0.45
Vitality 0.46 0.45 0.17 0.57 0.58
Social Function 0.54 0.55 0.21 0.56 0.65
Role Emotional 0.37 0.44 0.10 0.50 0.51
Mental Health 0.37 0.51 0.21 0.55 0.57
PCS 0.47 0.19 0.06 0.31 0.41
MCS 0.39 0.55 0.20 0.61 0.60
WOMAC
Pain -0.49 -0.35 -0.03 -0.58 -0.56
Stiffness -0.43 -0.27 -0.06 -0.51 -0.51
Physical Function -0.59 -0.37 -0.10 -0.56 -0.63
Total score -0.59 -0.37 -0.09 -0.59 -0.63
VAS
Average pain over 
past week
-0.50 -0.27 -0.07 -0.60 -0.56
Pain while resting 
over past week
-0.39 -0.25 -0.09 -0.54 -0.49
Restriction in ADL 
over past week
-0.59 -0.35 -0.10 -0.53 -0.59
Lequesne score 
(hip only)
-0.71 -0.52 -0.26 -0.66 -0.76
Note: Sample size for correlation between scales is n = 222 except for the Lequesne Index as it only relates to OA hip cases (n = 115).
Using Cohen's convention, the magnitude of the correlations can be viewed as; > 0.5 large, 0.5 to 0.3 moderate and < 0.3 weak [18].Table 3: Ability of the instruments to discriminate between OWL patients and community group








SD. t RE Area 
Under 
Curve
Asymptotic 95% CI Z APG % 95% CI
M SD. M SD Lower Upper Lower Upper
AQOL
Utility Score 0.50 0.19 0.37 0.25 0.66 0.21 3.7** 1.00 **0.67 0.57 0.77 referenc
e
Independent living 0.80 0.18 0.69 0.22 0.58 0.19 3.3** 0.79 *0.66 0.57 0.75 0.10 1.9 -16.6 20.5
Social relationships 0.84 0.15 0.76 0.26 0.24 0.19 2.4* 0.41 0.56 0.45 0.67 1.08 21.5 1.9 41.1
Physical senses 0.90 0.09 0.92 0.07 -0.26 0.08 -1.4 0.16 0.43 0.33 0.53 ^1.97 48.5 24.4 72.7
Psychological wellbeing 0.81 0.11 0.67 0.23 0.88 0.15 4.9** 1.78 *0.65 0.54 0.76 0.22 4.4 -15.2 23.9
SF-36
Physical function 40.8 21.0 29.8 24.9 0.50 22.2 2.8* 0.57 **0.67 0.57 0.77 -0.02 0.5 -22.7 23.8
Role physical 26.7 37.1 10.6 22.9 0.48 33.7 2.7* 0.53 *0.61 0.52 0.70 0.47 11.6 -12.3 35.5
Bodily pain 42.7 18.8 33.9 17.2 0.48 18.3 2.7* 0.53 *0.63 0.53 0.72 0.43 8.8 -11.1 28.7
General health 56.6 22.2 51.7 20.8 0.22 21.8 1.3 0.12 0.56 0.47 0.66 0.86 21.1 -3.0 45.2
Vitality 44.7 19.5 43.3 22.0 0.07 20.2 0.4 0.01 0.52 0.42 0.63 1.22 29.4 5.8 53.1
Social function 68.4 24.8 56.4 28.7 0.46 26.0 2.6* 0.49 *0.62 0.52 0.72 0.46 9.8 -11.2 30.9
R o l e  e m o t i o n a l 5 5 . 14 4 . 64 3 . 04 5 . 90 . 2 74 5 . 0 1.5 0.17 0.57 0.47 0.67 0.81 19.9 -4.2 44.0
Mental health 68.3 17.9 61.3 22.3 0.36 19.2 2.1* 0.30 0.59 0.48 0.69 0.69 16.5 -6.9 39.8
PCS 31.8 9.3 27.8 8.1 0.44 9.0 2.5* 0.46 *0.64 0.55 0.74 0.20 5.0 -19.5 29.4
MCS 47.8 11.6 44.9 13.4 0.24 12.1 1.4 0.13 0.56 0.46 0.66 0.91 21.4 -1.6 44.3
WOMAC
Pain 41.6 20.7 54.3 21.9 -0.60 21.0 -3.4** 0.84 *0.66 0.57 0.76 0.08 1.7 -20.3 0.2
Stiffness 50.0 18.5 59.4 18.9 -0.51 18.6 -2.9* 0.60 *0.63 0.53 0.72 0.37 8.3 -13.5 0.3
Physical function 42.5 19.4 58.5 19.3 -0.82 19.4 -4.7** 1.57 **0.71 0.62 0.80 -0.38 8.1 -12.8 0.3
T o t a l  s c o r e 4 2 . 91 8 . 45 7 . 71 9 . 0 -0.79 18.6 -4.5** 1.46 **0.70 0.61 0.79 -0.28 6.0 -14.7 0.3
VAS (over past week)
Average pain -43.7 23.8 -60.7 21.6 0.74 23.2 4.2** 1.26 **0.70 0.61 0.79 -0.28 6.0 -0.2 0.3
Pain at rest -26.9 22.2 -41.8 22.6 0.67 22.3 3.8** 1.03 **0.70 0.61 0.78 -0.22 5.0 -0.2 0.3
ADL Restriction -37.8 26.0 -51.2 23.9 0.53 25.4 3.0* 0.64 *0.65 0.56 0.74 0.18 3.9 -0.2 0.3
# Note: For the effect size calculations the Community group was nominated as the 'control group'. * p < 0.05, ** p < 0.001, ^ p > 0.05.
Table 4: Rank ordering of instrument performance by various discriminative tests for the known group comparisons
Effect Size RE ROC (AUC)
Self Rated Health 1 AQoL (-1.00) AQoL (1.00) AQoL (0.76)
2 WOMAC (0.92) WOMAC (0.84) WOMAC (0.75)
3 PCS (-0.84) PCS (0.71) PCS (0.67)
4 VAS pain (0.79) VAS pain (0.63) VAS pain (0.65)
OWL v Community 1 WOMAC (-0.79) WOMAC (1.57) WOMAC (0.70)
group 2 VAS pain (0.74) VAS pain (1.03) VAS pain (0.70)
3 AQoL (0.66) AQoL (1.00) AQoL (0.67)
4 PCS (0.44) PCS (0.46) PCS (0.64)
5 MCS (0.24) MCS (0.13) MCS (0.56)
Note: Comparison groups were Self-rated good vs. poor health and Orthopedic waiting list (OWL) vs. Community based group.Publish with BioMed Central    and   every 
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